Skip Navigation

JNCI Journal of the National Cancer Institute 1991 83(24):1797-1805; doi:10.1093/jnci/83.24.1797-a
© 1991 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Holmes, F. A.
Right arrow Articles by Raber, M. N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Holmes, F. A.
Right arrow Articles by Raber, M. N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 83, No. 24, 1797-1805, December 18, 1991
© 1991 Oxford University Press

Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer

Frankie Ann Holmes*, Ronald S. Walters, Richard L. Theriault, Aman U. Buzdar, Debra K. Frye, Gabriel N. Hortobagyi, Arthur D. Forman, Lesley K. Newton, Martin N. Raber

Section of Breast Medical Oncology, Department of Medical Oncology, The University of Texas M. D. Anderson Cancer Center Houston, Tex
Division of Medicine, Department of Neuro Oncology, The University of Texas M. D. Anderson Cancer Center
Clinical Trials Administration, Department of Medical Oncology, The University of Texas M. D. Anderson Cancer Center

*Frankie Ann Holmes, M.D., The University of Texas M. D. Anderson Cancer Center-Box 95, 1515 Holcombe Blvd., Houston TX 77030.

Taxol, an antimicrotubule agent, has shown promise for efficacy in treatment of breast cancer, but severe hypersensitivity reactions led to cessation of many phase I clinical trials. Consequently, investigators and the National Cancer Institute recommended that phase I and II studies of this agent use 24-hour infusions and antiallergic medications. Using a premedication regimen effective in preventing hypersensitivity reactions, we have performed a phase II trial of taxol in patients with metastatic breast cancer. Taxol was administered to 25 patients at a dose of 250 mg/m2 by 24-hour infusion every 21 days. These patients had received only one prior chemotherapy regimen, either adjuvant to surgery or for metastatic disease; all but two had received doxorubicin. In 60% of the patients, the dominant site of disease was the viscera. All patients were assessable. In April 1991, at a median time on study of 9 months (range, 5–13+months), the objective response rate was 56% (12% complete and 44% partial; 95% confidence interval, 35%–76%). Disease progressed in only 8% of the patients. The median number of courses of therapy was 11. Granulocytopenia was the dose-limiting toxic effect, but neutropenia with fever occurred in only 5% of 232 courses. A chronic glove-and-stocking neuropathy developed in most patients, but no altergic reactions occurred. We conclude that taxol is an active agent in the treatment of metastatic breast cancer and that it warrants continued study. Currently, we are conducting a phase I trial of taxol plus doxorubicin. Future trials should address the optimal effective dose, the optimal sequencing of combinations, mechanisms of drug resistance in tumors, and dose-limiting toxic effects (particularly cardiac toxic effects of taxol given as a single agent or in drug combinations).


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anticancer ResHome page
A. POLYZOS, H. GOGAS, C. MARKOPOULOS, N. TSAVARIS, O. PAPADOPOULOS, K. POLYZOS, and A. GIANNOPOULOS
Salvage Chemotherapy with Oxaliplatin and Capecitabine for Breast Cancer Patients Pretreated with Anthracyclines and Taxanes
Anticancer Res, July 1, 2009; 29(7): 2851 - 2856.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Gianni, J. Baselga, W. Eiermann, V. G. Porta, V. Semiglazov, A. Lluch, M. Zambetti, D. Sabadell, G. Raab, A. L. Cussac, et al.
Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer
J. Clin. Oncol., May 20, 2009; 27(15): 2474 - 2481.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
D. Mauri, N. P. Polyzos, G. Salanti, N. Pavlidis, and J. P. A. Ioannidis
Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer
J Natl Cancer Inst, December 17, 2008; 100(24): 1780 - 1791.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
J. Matsubara, Y. Shimada, A. Takashima, D. Takahari, Y. Hirashima, N. T. Okita, T. E. Nakajima, K. Kato, T. Hamaguchi, Y. Yamada, et al.
A Phase I Study of Bolus 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel (FLTAX) as First-line Therapy for Advanced Gastric Cancer
Jpn. J. Clin. Oncol., August 1, 2008; 38(8): 540 - 546.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
K. Bullock and K. Blackwell
Clinical Efficacy of Taxane-Trastuzumab Combination Regimens for HER-2-Positive Metastatic Breast Cancer
Oncologist, May 1, 2008; 13(5): 515 - 525.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. E. Karp and S. Broder
Oncology
JAMA, July 15, 1992; 268(3): 391 - 393.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.